Board of directors

Mr Mott has been a member of the Company's Board since October 31, 2007. He is also a member of the Company's Audit, Compliance & Risk Committee. Mr Mott joined venture capital firm New Enterprise Associates ('NEA') in September 2008 as a General Partner focused on biopharmaceutical investments. Prior to joining NEA, Mr Mott was President and Chief Executive Officer of MedImmune Inc., a subsidiary of AstraZeneca PLC, and Executive Vice President of AstraZeneca. He joined MedImmune in 1992 and served in roles of increasing responsibility including Chief Operating Officer, Chief Financial Officer, President and Chief Executive Officer. Prior to joining MedImmune, Mr Mott was a Vice President in the Health Care Investment Banking Group at Smith Barney, Harris Upham & Co. Inc. Mr Mott is a member of the board of Rib-x Pharmaceuticals and of the St. Albans School. He is a former board member of Ambit Biosciences, Conceptis Technologies, and MedImmune, Inc. and has served on numerous industry trade group and not-for-profit boards. Mr Mott holds a bachelor's degree in economics and government from Dartmouth College.